Xun Meng

Title: Xun Meng: Innovator in Antibody Research

Introduction

Xun Meng is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of antibody research, holding a total of 6 patents. His work focuses on developing antibodies for therapeutic and diagnostic purposes, particularly in relation to specific receptors.

Latest Patents

Xun Meng's latest patents include innovative antibodies specific to folate receptor alpha, also known as folate receptor 1 or FOLR1. These antibodies have potential applications in both therapeutic and diagnostic settings. Additionally, he has developed chimeric antigen receptors (CARs) that incorporate an extracellular antigen-binding fragment targeting FOLR1, which can be expressed by immune cells. Another significant patent involves antibodies specific to MUC18, also referred to as MCAM or CD146, along with their uses for therapeutic and diagnostic purposes. Similar to his work with FOLR1, he has also created CARs that bind MUC18 and can be expressed by immune cells.

Career Highlights

Throughout his career, Xun Meng has worked with notable companies such as Multitude, Inc. and Abmart (Shanghai) Co., Ltd. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Xun Meng has collaborated with esteemed colleagues, including Bing Hou and Shu-Hui Liu. These partnerships have further enriched his research endeavors and expanded the impact of his work in the field of antibody development.

Conclusion

Xun Meng is a distinguished inventor whose work in antibody research has led to significant advancements in therapeutic and diagnostic applications. His innovative patents and collaborations highlight his commitment to improving healthcare through scientific innovation.